These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 27279912)

  • 21. AXL is an essential factor and therapeutic target for metastatic ovarian cancer.
    Rankin EB; Fuh KC; Taylor TE; Krieg AJ; Musser M; Yuan J; Wei K; Kuo CJ; Longacre TA; Giaccia AJ
    Cancer Res; 2010 Oct; 70(19):7570-9. PubMed ID: 20858715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma.
    Fleuren ED; Hillebrandt-Roeffen MH; Flucke UE; Te Loo DM; Boerman OC; van der Graaf WT; Versleijen-Jonkers YM
    Oncotarget; 2014 Dec; 5(24):12753-68. PubMed ID: 25528764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
    Brand TM; Iida M; Stein AP; Corrigan KL; Braverman CM; Coan JP; Pearson HE; Bahrar H; Fowler TL; Bednarz BP; Saha S; Yang D; Gill PS; Lingen MW; Saloura V; Villaflor VM; Salgia R; Kimple RJ; Wheeler DL
    Clin Cancer Res; 2015 Jun; 21(11):2601-12. PubMed ID: 25767293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model.
    Chen TJ; Mydel P; Benedyk-Machaczka M; Kamińska M; Kalucka U; Blø M; Furriol J; Gausdal G; Lorens J; Osman T; Marti HP
    Physiol Rep; 2021 Dec; 9(23):e15140. PubMed ID: 34877810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hematopoietic progenitor kinase 1 down-regulates the oncogenic receptor tyrosine kinase AXL in pancreatic cancer.
    Song X; Akasaka H; Wang H; Abbasgholizadeh R; Shin JH; Zang F; Chen J; Logsdon CD; Maitra A; Bean AJ; Wang H
    J Biol Chem; 2020 Feb; 295(8):2348-2358. PubMed ID: 31959629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma.
    Bae CA; Ham IH; Oh HJ; Lee D; Woo J; Son SY; Yoon JH; Lorens JB; Brekken RA; Kim TM; Han SU; Park WS; Hur H
    Gastric Cancer; 2020 Sep; 23(5):824-836. PubMed ID: 32239298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.
    Mishra A; Wang J; Shiozawa Y; McGee S; Kim J; Jung Y; Joseph J; Berry JE; Havens A; Pienta KJ; Taichman RS
    Mol Cancer Res; 2012 Jun; 10(6):703-12. PubMed ID: 22516347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway.
    Shen H; Li L; Yang S; Wang D; Zhong S; Zhao J; Tang J
    Gene; 2016 Nov; 593(1):84-90. PubMed ID: 27523474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extracellular 5'-nucleotidase (CD73) promotes human breast cancer cells growth through AKT/GSK-3β/β-catenin/cyclinD1 signaling pathway.
    Yu J; Wang X; Lu Q; Wang J; Li L; Liao X; Zhu W; Lv L; Zhi X; Yu J; Jin Y; Zou Q; Ou Z; Liu X; Zhou P
    Int J Cancer; 2018 Mar; 142(5):959-967. PubMed ID: 29047106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AXL is an oncotarget in human colorectal cancer.
    Martinelli E; Martini G; Cardone C; Troiani T; Liguori G; Vitagliano D; Napolitano S; Morgillo F; Rinaldi B; Melillo RM; Liotti F; Nappi A; Bianco R; Berrino L; Ciuffreda LP; Ciardiello D; Iaffaioli V; Botti G; Ferraiolo F; Ciardiello F
    Oncotarget; 2015 Sep; 6(27):23281-96. PubMed ID: 25966280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.
    Antony J; Zanini E; Kelly Z; Tan TZ; Karali E; Alomary M; Jung Y; Nixon K; Cunnea P; Fotopoulou C; Paterson A; Roy-Nawathe S; Mills GB; Huang RY; Thiery JP; Gabra H; Recchi C
    EMBO Rep; 2018 Aug; 19(8):. PubMed ID: 29907679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway.
    Sawabu T; Seno H; Kawashima T; Fukuda A; Uenoyama Y; Kawada M; Kanda N; Sekikawa A; Fukui H; Yanagita M; Yoshibayashi H; Satoh S; Sakai Y; Nakano T; Chiba T
    Mol Carcinog; 2007 Feb; 46(2):155-64. PubMed ID: 17186543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.
    Hector A; Montgomery EA; Karikari C; Canto M; Dunbar KB; Wang JS; Feldmann G; Hong SM; Haffner MC; Meeker AK; Holland SJ; Yu J; Heckrodt TJ; Zhang J; Ding P; Goff D; Singh R; Roa JC; Marimuthu A; Riggins GJ; Eshleman JR; Nelkin BD; Pandey A; Maitra A
    Cancer Biol Ther; 2010 Nov; 10(10):1009-18. PubMed ID: 20818175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gas6 attenuates lipopolysaccharide‑induced TNF‑α expression and apoptosis in H9C2 cells through NF‑κB and MAPK inhibition via the Axl/PI3K/Akt pathway.
    Li M; Ye J; Zhao G; Hong G; Hu X; Cao K; Wu Y; Lu Z
    Int J Mol Med; 2019 Sep; 44(3):982-994. PubMed ID: 31524235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies.
    Kariolis MS; Miao YR; Diep A; Nash SE; Olcina MM; Jiang D; Jones DS; Kapur S; Mathews II; Koong AC; Rankin EB; Cochran JR; Giaccia AJ
    J Clin Invest; 2017 Jan; 127(1):183-198. PubMed ID: 27893463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
    Al-Dhfyan A; Alhoshani A; Korashy HM
    Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.
    Rankin EB; Fuh KC; Castellini L; Viswanathan K; Finger EC; Diep AN; LaGory EL; Kariolis MS; Chan A; Lindgren D; Axelson H; Miao YR; Krieg AJ; Giaccia AJ
    Proc Natl Acad Sci U S A; 2014 Sep; 111(37):13373-8. PubMed ID: 25187556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential expression of Axl and correlation with invasion and multidrug resistance in cancer cells.
    Zhao Y; Sun X; Jiang L; Yang F; Zhang Z; Jia L
    Cancer Invest; 2012 May; 30(4):287-94. PubMed ID: 22489801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.
    Quinn JM; Greenwade MM; Palisoul ML; Opara G; Massad K; Guo L; Zhao P; Beck-Noia H; Hagemann IS; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
    Mol Cancer Ther; 2019 Feb; 18(2):389-398. PubMed ID: 30478151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of AKT phosphorylation by GSK3β and PTEN to control chemoresistance in breast cancer.
    Gao C; Yuan X; Jiang Z; Gan D; Ding L; Sun Y; Zhou J; Xu L; Liu Y; Wang G
    Breast Cancer Res Treat; 2019 Jul; 176(2):291-301. PubMed ID: 31006103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.